26 April 2017
Venn Life Sciences Holdings Plc
("Venn" or the "Company")
Result of Annual General Meeting
Venn Life Sciences Holdings plc (AIM: VENN), a growing Contract Research Organisation (CRO) providing drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces that, at the Annual General Meeting held earlier today, all resolutions proposed were duly passed.
Enquiries:
Venn Life Sciences Holdings Plc
Allan Wood, Non-Executive Chairman Tony Richardson, Chief Executive Officer |
Tel: +353 1 5499341 |
Davy (Nominated Adviser and Broker)
Fergal Meegan / Matthew de Vere White (Corporate Finance) Orla Bolger (Corporate Broking) |
Tel: +353 1 679 6363 |
Hybridan LLP (Co-Broker)
Claire Louise Noyce |
Tel: +44 (0)20 3764 2341 |
Walbrook PR Ltd |
Tel: +44(0)20 7933 8787 |